Prospective analysis of patient‐reported outcomes and physician‐reported outcomes with gynecologic cancer chemotherapy
Journal of Obstetrics and Gynaecology Research · 2024
DOI: 10.1111/jog.15811 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2024. Verfasst von Tomo Takenaga und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki, Japan. Hauptthemen laut MEDLINE: Chemoradiotherapy, Genital Neoplasms, Female. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objective
Gynecologic cancer chemotherapy impacts the quality of life (QOL) of patients, with lasting adverse events that may require treatment adjustments or discontinuation. Consequently, real‐time symptom monitoring before outpatient visits has resulted in improved QOL for patients and extended survival times. This study investigated whether there are differences between electronic patient‐reported outcomes (e‐PRO‐CTCAE) and physician‐assessed outcomes (NCI‐CTCAE) evaluated in an outpatient setting in gynecologic cancer chemotherapy.
Methods
The study was conducted on 50 patients who received their first chemotherapy treatment at St. Marianna University Hospital Obstetrics and Gynecology from July 1, 2021 to December 31, 2022. PRO‐CTCAE and NCI‐CTCAE were evaluated at each instance of chemotherapy and 2 weeks after. The PRO‐CTCAE was additionally collected weekly using e‐PRO.
Results
The values for “Joint Pain,” “Nausea,” “Taste Disturbance,” “Constipation,” “Insomnia,” “Fatigue,” “Limb Edema,” and “Concentration Impairment” were consistently higher in PRO‐CTCAE than in NCI‐CTCAE, indicating that physicians underestimated the severity of adverse events. In contrast, there was no significant difference in “Peripheral Neuropathy,” demonstrating that physicians had a good understanding of this condition in patients. The weekly responses obtained from e‐PRO revealed that symptom exacerbations peaked outside of clinic visits.
Conclusions
This study demonstrated physicians tend to underestimate most adverse events. Moreover, the responses using e‐PRO revealed peak symptom deterioration occurred outside of outpatient visits. This suggested that e‐PRO and actions taken in response to them can improve patients' QOL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki, Japan.
- Pathophysiology and Bioregulation, St. Marianna University Graduate School of Medicine, Kawasaki, Japan.
- Department of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan.
ORCID-Profile: Tomo Takenaga, Shiho Kuji, Ken-Ichiro Tanabe, Haruhiro Kondo, Tatsuru Ohara, Tsuguo Iwatani, Nao Suzuki
Zitieren
APA
Takenaga, T., Kuji, S., Tanabe, K. I., Kanamori, R., Imai, H., Takeuchi, J., Kondo, H., Ohara, T., Iwatani, T., & Suzuki, N. (2024). Prospective analysis of patient‐reported outcomes and physician‐reported outcomes with gynecologic cancer chemotherapy. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.15811
Vancouver
Takenaga T, Kuji S, Tanabe KI, Kanamori R, Imai H, Takeuchi J, et al. Prospective analysis of patient‐reported outcomes and physician‐reported outcomes with gynecologic cancer chemotherapy. Journal of Obstetrics and Gynaecology Research. 2024. doi:10.1111/jog.15811
BibTeX
@article{Takenaga2024,
author = {Takenaga, Tomo and Kuji, Shiho and Tanabe, Ken-Ichiro and Kanamori, Ryo and Imai, Haruka and Takeuchi, Jun and Kondo, Haruhiro and Ohara, Tatsuru and Iwatani, Tsuguo and Suzuki, Nao},
title = {Prospective analysis of patient‐reported outcomes and physician‐reported outcomes with gynecologic cancer chemotherapy},
journal = {Journal of Obstetrics and Gynaecology Research},
year = {2024},
doi = {10.1111/jog.15811}
}
EUVIMED